Do Patients with Multiple Sclerosis Derive More Benefit from Robot-Assisted Gait Training Compared with Conventional Walking Therapy on Motor Function? A Meta-analysis

Xiao Xie 1†, Hao Sun 2†, Qing Zeng 1, Pengcheng Lu 1, Yijin Zhao 1, Tao Fan 1 and Guozhi Huang 1*

1Department of Rehabilitation, Zhujiang Hospital, Southern Medical University, Guangzhou, China, 2The Guangdong General Hospital, Guangzhou, China

Objective: To determine whether robot-assisted gait training (RAGT) is more effective in improving mobility, endurance, gait performance, and balance in patients with multiple sclerosis (MS) compared with conventional walking rehabilitation treatment (CWT).

Data sources: Sources included the Cochrane Library, PubMed, Embase, and Science Direct databases.

Review method: All possible articles were retrieved by two independent investigators and relevant articles were gathered. Studies on adult patients (older than 19 years old) suffering from MS were included, regardless the subtype of MS diagnosis. Finally, we identified seven studies that comprised 205 patients with MS.

Results: We identified seven studies comprising 205 patients with MS in our meta-analysis. The pooled mean difference (MD) for the six-minute walk test (6MWT) was 14.25 [95% confidence interval (CI) 3.19 to 25.32, Z = 2.53, P = 0.01, I² = 54%], which indicates that RAGT is superior to CWT on improving endurance. No significant improvement on using RAGT was found regarding the Berg Balance Scale (MD = −0.59, 95% CI: −2.7 to 1.52, Z = 0.55, P = 0.58, I² = 51%), 10-meter walk test [standard mean difference (SMD) = 0.03, 95% CI: −0.26 to 0.31, Z = 0.18, P = 0.86, I² = 48%] timed up and go (TUG) test (MD = −1.04, 95% CI: −8.68 to 6.60, Z = 0.27, P = 0.79), or stride length (SMD = 0.36, 95% CI: −0.13 to 0.85, Z = 0.73, P = 0.15).

Conclusion: We can conclude that RAGT can bring more benefits on improving 6MWT among MS patients, but it is not enough to make a clinically significance conclusion. Considering the limitation of our study, it takes reservations about recommending all MS patients to take RAGT as primary rehabilitation intervention. Unless patients with

Abbreviations: MS, multiple sclerosis; BWSTT, body-weight supported treadmill training; RAGT, robot-assisted gait training; CWT, conventional walking rehabilitation treatment; RCTs, randomized controlled trials; 10MWV, ten-meter walk velocity; 6MWT, six-minute walk test; BBS, Berg Balance Scale; TUG, timed up and go test; SL, stride length.
INTRODUCTION

Approximately 75% of multiple sclerosis (MS) patients experience mobility problems. Gait rehabilitation, which can increase patients' levels of activity and participation, thus increasing their independence, is of utmost importance (1). Physiotherapy has been shown to be effective for improving gait function compared with no treatment among MS patients (2).

However, traditional over-ground walking training is associated with a high fall risk during treatment for patients with more severe gait disabilities and cannot be conducted in the early stage of rehabilitation (3). An alternative treatment for these patients is body-weight supported treadmill training (BWSTT), which enables early initiation of gait training and has been shown to be effective in patients who have had a stroke (4–6). However, among MS patients, few studies have found BWSTT to be more effective than the traditional over-ground walking training. The manual administration of BWSTT is difficult and greatly depends on the physiotherapist's abilities, thus making BWSTT inefficient (7, 8).

To facilitate the delivery of BWSTT, robot-assisted gait training (RAGT) was recently developed, and it has many advantages over BWSTT and conventional walking treatment. The RAGT is reproducible, stable, more physiological, and measurable (9). However, series of clinical trials tried to verify whether RAGT is more effective or not, but failed to gain positive results. On one hand, the small number of MS patients treated by RAGT in these studies lead to low statistical power. On the other hand, trials and animal test have proved that Lokomat has limitations in precisely replicating a normal gait, as it restricts the movement of the trunk and pelvis and induces a different muscle activation pattern for the lower limbs. Although its results are based solely on the kinematic pattern which was adjusted according to the feeling of the patients. And only animal experiment was conducted to verify variable training paradigms appears to be a more effective rehabilitative strategy than the fixed training paradigm. So, the question remains open with regard to whether RAGT offers better outcome than regular physiotherapy (10).

To date, no meta-analysis has been conducted regarding gait function rehabilitation by RAGT for patients with MS. The objective of this study was to determine whether people suffering from MS could benefit more from RAGT compared with conventional walking rehabilitation treatment (CWT) on motor function.

MATERIALS AND METHODS

Literature Search
A comprehensive search was conducted in the Cochrane Library, Science Direct, and PubMed databases prior to 2016. Two reviewers (Xie X and Sun H) independently searched articles in electronic databases above using the search strategy “((((MS) OR disseminated sclerosis) OR encephalomyelitis disseminate)) AND (((((RAGT) OR robot-assisted gait rehabilitation) OR robotic-assisted gait rehabilitation) OR robotic walking therapy) OR robotic locomotor training) OR robotic-assisted locomotor training)) AND (((CWT) OR conventional physical therapy) OR Conventional therapy).” Reference lists from related articles were also reviewed. The language was restricted to English. All possible articles were retrieved by two independent investigators and relevant articles were gathered. The search strategy was also presented as a Data Sheet S1 in Supplementary Material.

Type of Studies
Studies on adult patients (over 19 years old) suffering from MS were included, regardless the subtype of MS diagnosis, as were effect studies on RAGT that encompassed improving gait function and gait-related outcome measurements. Studies were also included if at least one of the intervention groups received RAGT exclusively as an intervention. Studies where RAGT was used in combination with interventions other than BWS were excluded. For example, if RAGT was combined with functional electrostimulation, the study was excluded. Studies with outcomes focused exclusively on physical capacity, electromyography or kinematic data, and/or cardiorespiratory functioning were excluded. Animal studies and studies on children also were excluded. Pre-, quasi-, and true-experimental studies were included.

Study Selection and Data Extraction
All studies included met the following criteria:

1. Must be random clinical trials (included pilot random clinical trials).
2. Language restriction was not applied, and the nationality and race of research subjects were not restricted.
3. Trials included must compare the RAGT and CWT.
4. The primary outcome is six-minute walk test (6MWT), 10MWD, Berg Balance Scale (BBS) and the secondary outcome is some other gait parameters [e.g., stride length (SL)].

Studies containing the following criteria have been excluded:

1. The research failed to provide the key information, such as the total number of patients.
2. Studies were excluded if RAGT was used in combination with interventions other than BWSTT (body-weight support treadmill training).
3. Studies were excluded if outcomes focused exclusively on physical capacity, electromyography or kinematic data, and/or cardiorespiratory functioning. Animal studies and studies on children also were excluded.
Type of Outcomes
Improving activity and participation is as important as reducing impairments among patients suffering from MS. The walking speed is a performance measure used to evaluate functional mobility, gait, and vestibular function. The outcome of the walking speed has been shown to have excellent correlation with dependence in self-care and domestic life among patients with MS (11). 6MWT was used as a performance-based measure of functional exercise capacity. The BBS is a 14-item objective measure designed to assess static balance and fall risk in adult populations. This measure is highly recommended by the American Physical Therapy Association’s MS Taskforce (MSEDGE) to be conducted among patients suffering from MS. Other outcomes are used as secondary outcomes.

1. Primary outcomes:
   (1) Mobility [e.g., 6MWT, 20- or 10-meter walk test (10MWT), gait speed]
   (2) Gait performance [e.g., timed up and go test (TUG)]
   (3) Balance (BBS)

2. Secondary outcomes:
   (1) Gait parameters (e.g., SL)

Statistical Analysis
Means and SD were determined for each outcome in each treatment group. For the combined data weighted mean difference, mean difference (MD) and 95% confidence interval (CI) were computed. Review Manager 5.3 software (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark) was used for all analyses. The results of the meta-analysis are presented using forest plots. The heterogeneity of the included studies was quantified by the $I^2$ statistic, which indicates the percentage of variation across studies due to heterogeneity. A fixed effects model was used to combine studies when the $I^2$ value was less than 60%. Otherwise, the random effects model was used (12).

Bias risks were assessed according to the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions by two independent authors (12). Disagreements were resolved through consensus. Publication bias was not assessed because there were only seven studies in the meta-analysis, and the test power would have been too low to distinguish change from real asymmetry (13).

RESULTS
According to the inclusion criteria, we identified seven studies that comprised 205 patients with MS (14–19). The flow diagram of the study selection is presented in Figure 1. All seven studies were conducted with random sequence generation, the quality evaluations of each clinical trials are listed in Table 2. The risk of bias in the included studies was assessed using the standard Cochrane Collaboration tool. All of the included randomized controlled trials (RCTs) with straight random principles were suggested to have a low risk, despite the lack of double-blinding, so the assessments were considered to be non-biased. The individual prognostic factors (e.g., age, gender, and performance status) were all well-balanced within these studies.
| Reference                  | Num | Male/female | Expanded Disability Status Scale (EDSS) score | Age | Intervention (+comparison) | Outcome | Assessment times               |
|----------------------------|-----|-------------|-----------------------------------------------|-----|---------------------------|---------|------------------------------|
| Lo and Triche (19)         | 13  | 7 m/6 f     | robot-assisted gait training (RAGT) 3 m/3 f   |     | RAGT: 5.0 (1.6); BWSTT: 4.9 |         | 25-foot walk (T25FW), 6-min walk double support time (DST) |
|                            |     |             | body-weight supported treadmill training (BWSTT) |     | RAGT: BWSTT + Lokomat (n = 6), 2 sessions/week for 6 weeks |         | Baseline Phase I              |
| Beer et al. (18)           | 29  | 12 m/23 f   | RAGT: 7 m/12 f                               |     | RAGT: 49.7 (SD 11); CWT: 51 (SD 15.5) |         | Walking speed (20MWT), walking endurance (6MWT), stride length (SL) (cm) |
|                            |     |             |                                               |     | BWSTT (n = 15), 5 sessions/week for 3 weeks |         | Baseline, after 3 weeks and at follow-up after 6 months |
| Gijbels et al. (22)        | 49  | 14 m/15 f   | RAGT: 5.9 (range: 6–7.5); CWT: 6.5 (range: 6–7.5) |     | RAGT: BWSTT + Lokomat (n = 14), 5 sessions/week for 3 weeks |         | Walking speed (10MWT, 3MWOT on 80 m hallway) |
|                            |     |             |                                               |     | CWT: walking in group with physiotherapist (n = 23), 30 min/session 9 session |         | Baseline, after treatment |
| Schwartz et al. (17)       | 28  | 14 m/15 f   | RAGT: 6.2 (range: 5.5–7); CWT: 6 (range: 5–7) |     | RAGT: BWSTT + Lokomat (n = 16), 2–3 sessions/week for 6 weeks |         | Walking speed (10MWT), walking endurance (6MWT), disability (EDSS) |
|                            |     |             |                                               |     | CWT: Gait and dynamic balance exercises (n = 17), 2–3 sessions/week for 6 weeks |         | Baseline, after 4 weeks, follow-up after 3 and 6 months |
| Straudi et al. (15)        | 16  | 5 m/11 f    | RAGT: 5.8 ± 0.8; CWT: 5.7 ± 0.7              |     | RAGT: Lokomat (n = 6), 2 sessions/week for 6 weeks |         | Six-minute walk test (6MWT) timed up and go test (TUG) gait speed, cadence, double support, step length, step time |
|                            |     |             |                                               |     | CWT: lower-imb and lower-limb muscles exercises (n = 8), 2 sessions/week for 6 weeks |         | Week prior to treatment initiation (T0), the week after the end of treatment (T1) and at 3 months’ follow-up (T2) |
| Gandolfi et al. (14)       | 24  | 6 m/16 f    | RAGT: 3.96 (0.75); SIBT 4.35 (8.42)          |     | RAGT: electromechanical Gait Trainer GT1 (Reha-Stm, Berlin, Germany) (n = 12), 2–3 sessions/week for 6 weeks |         | Gait speed (cm/s) Berg Balance Scale (BBS) GAITRite System: gait speed, cadence, double support, step length, step time |
|                            |     |             |                                               |     | SIBT: sensory integration balance training (n = 12), 2–3 sessions/week for 6 weeks |         | Baseline (T0), after treatment (T1) and at 1-month follow-up (T2) |
| Straudi et al. (20)        | 58  | 18 m/34 f   | RAGT: 6.43 (0.36); CWT 6.46 (0.43)           |     | RAGT: Lokomat (n = 27, 2–3 sessions/week for 6 weeks) |         | 10MWV/6MWT/BBS/TUG/SL/SF |
|                            |     |             |                                               |     | CWT N = 25, 2–3 sessions/week for 6 weeks |         | Baseline, after 4 week, follow-up after 3 and 6 months |

RAGT is Superior than CWT
Among all included studies, Sofia and Beer et al. (18, 20) limit the inclusion criteria to severe gait impairments as evidenced by a rating on the Expanded Disability Status Scale (EDSS) between 6.0 and 7.0. All studies set Lokomat as the treatment of RAGT group except Gandolfi et al. (14) (electromechanical Gait Trainer). The therapy sessions differ from 9 to 12. All the patient characteristics, such as gender, EDSS score, and age, are summarized in Table 1. Different protocols of reporting among the included studies are also reported in Table 1. In our analysis, four studies measured walking speed by the 10MWT. Walking endurance was measured with the 6MWT in three studies. Balance function rehabilitation among patients was evaluated by the BBS in three RCTs. Other gait parameters, including gait speed, cadence, double support time (DST), and SL, were reported in different studies. Straudi et al. (15) and Gandolfi et al. (14) also used the GAIT-Rite mat to measure several of the gait parameters noted above.

**Table 2** The risk bias of included studies.

| Risk domains                        | Lo and Triche (19) | Beer et al. (18) | Vaney et al. (16) | Schwartz et al. (17) | Straudi et al. (15) | Gandolfi et al. (14) | Straudi et al. (20) |
|-------------------------------------|-------------------|------------------|-------------------|---------------------|---------------------|---------------------|---------------------|
| Random sequence generation          | Yes               | Yes              | Yes               | Yes                 | Yes                 | Yes                 | Yes                 |
| Allocation concealment              | Yes               | Yes              | Yes               | Yes                 | Yes                 | Yes                 | Yes                 |
| Blinding of participants and personnel | No                 | No           | Yes               | Yes                 | No                  | No                  | Yes                 |
| Blinding of outcome assessment       | No                 | No               | No                | Yes                 | No                  | No                  | Yes                 |
| Incomplete outcome data             | No                 | No               | No                | No                  | No                  | No                  | No                  |
| Selective reporting                 | No                 | No               | No                | No                  | No                  | No                  | No                  |

**Walking Speed**

Four studies measured walking speed using 10MWT, and two study using gait speed directly. All raw data are listed in Data Sheet 1 in Supplementary Material. The pooled standard mean difference (SMD) for the walking speed was 0.03 (95% CI: −0.26 to 0.31, Z = 0.18, P = 0.86, I² = 48%), no significant differences were observed between RAGT and the control group (Figure 2).

**Endurance**

Five studies measured exercise endurance using the 6MWT. Because all of the baseline data included are in balance, we used the raw data directly to compute the pooled MD, which resulted MD = 14.25 (95% CI: 3.19 to 25.32, Z = 2.53, P = 0.01, I² = 54%), indicating that RAGT is statistically superior to CWT on improving endurance (Figure 3). Four trials (15, 17) also reported follow-up data, so we performed a sensitivity analysis based on the different time points (MD 8.07, 95% CI: −5.48 to 21.61, Z = 1.17, P = 0.21, I² = 45%). However, there is no significant difference between RAGT and CWT about long-term effect for improving endurance (Figure 3).

**Balance**

Four trials reported the outcome of the BBS in MS subjects. The pooled MD was −0.59 (95% CI: −2.7 to 1.52, Z = 0.55, P = 0.58,
No clinically significant difference was observed (Figure 4). It suggests that RAGT cannot bring more benefits on improving static balance among MS patients.

**Gait Performance and Gait Parameters**

**Timed Up and Go Test**

We summarized the results for the effects of RAGT on gait performance as measured by the TUG, which is used to assess mobility, balance, walking ability, and fall risk in older adults. Both post-intervention and follow-up data from three studies were analyzed. However, no significant differences were observed between the RAGT group and the control group regarding TUG (post-intervention: MD = −1.04, 95% CI: −8.68 to 6.60, Z = 0.27, P = 0.79; follow-up: MD = −1.29, 95% CI: −11.16 to 8.57, Z = 0.26, P = 0.80) (Figure 5).

**Stride Length**

Stride length was reported in three studies that were used to calculate the pooled SMDs. No significant difference was observed between the RAGT group and the control group (SMD = 0.36, 95% CI: −0.13 to 0.85, Z = 0.73, P = 0.45) (Figure 6).

**DISCUSSION**

Recommendations from MSEDGE (Neurology Section of the American Physical Therapy Association’s Multiple Sclerosis Taskforce) suggest that the increase in walking distance of 6MWT is correlated with better self-care, mobility, and domestic life. Several studies also showed that the walking capacity tests (6MWT or 2MWT eta) are highly correlated with habitual walking performance in MS.

Estimating the SD of changes from baseline may cause an imprecise result, so we use the difference between baseline and post-intervention to calculate the MD or SMD for a higher degree of certainty. Based on the latest data up to 2016, this meta-analysis suggests that RAGT can derive more benefit for patients with MS in improving endurance to some extent. But it seems that it is not enough to make a clinically significant conclusion based on the
result. We found an improvement of 14.25 m in RAGT group, less than the minimally important change (22 m) for walking improvement from the patient perspective (21). Although this meta-analysis conducts a significant statistical difference ($P$-value ≤ 0.05) in the 6MWT among groups, it is too rash to demonstrate that RAGT can bring significantly clinical benefits so far.

Ten-meter walk test, which can assess the short duration walking speed. It has been proved to be a responsive test well suited to evaluate clinical interventions in various patient populations including stroke, Parkinson’s disease, general neurologic movement disorders. But our analysis did not reveal any statistically significant differences in the 10MWT between RAGT and control group. So, it suggests that RAGT cannot bring more benefit for patients in improving walking speed during short-distance walking. One possible explanation is that long-distance, rather short-distance, tests are more suitable in detecting improvements after rehabilitation for MS patients (22, 23).

On the other hand, it also has been reported that different types of walking training lead to differences in biomechanics and physiology (10, 24–26). One clinical concern that is often raised with Lokomat gait training is the lack of variability in the gait patterns. As RAGT is often run with 100% guidance force, patients are kept in a particular gait pattern, regardless of the subject’s intentions. Consequently, the participants lack the ability to vary their kinematic patterns from step to step. The ability to adjust gait pattern plays an important role during dynamic walking procedures. This finding may explain why RAGT cannot bring more effective motor function rehabilitation compared to CWT among MS patients, according to the outcome of the 10MWT. As only Lokomat restricting free trunk movements among RAGTs, analyze whether the obtained effects on walking endurance and balance are different in studies with Lokomat versus other robots which do not restrict the trunk is necessary. But only one study (14) included in our analyses used electromechanical Gait Trainer (Reha-Stim, Berlin, Germany) other than Lokomat, we cannot conduct a subgroup analysis due to the limit data. Further studies should aim at adjusting the working pattern of Lokomat and gain more improvements in precisely replicating a normal gait.

For functional balance tests, the BBS is generally considered the gold standard (27). The BBS is also an ideal measurement to evaluate the benefit of an intervention as a response to change.

### Table 1: Mean Differences in Walking Distance

| Study or Subgroup | RAGT Mean | SD | Total | CWT Mean | SD | Total | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|-----------|----|-------|----------|----|-------|-----------------------------------|-----------------------------------|
| 2.5.1 Posttreatment | Isabella Schwartz (2012) | -6.5 | 9.1 | 12 | -3.2 | 8 | 16 | 18.4% | -3.30 [-9.77, 3.17] |
| | S. Straudi (2013) | -5.9 | 10 | 8 | 0.6 | 2.4 | 8 | 17.4% | -6.50 [-13.63, 0.63] |
| | Sofia Straudi (2015) | 2.66 | 13.79 | 26 | -3.96 | 10.5 | 23 | 17.9% | 6.62 [-0.20, 13.44] |
| | Subtotal (95% CI) | 53.6% | 46 | | | | | -1.04 [-8.68, 6.60] |
| Heterogeneity: $\tau^2 = 33.52$, $Chi^2 = 7.57$, $df = 2$ ($P = 0.02$); $I^2 = 74$% |
| Test for overall effect: $Z = 0.27$ ($P = 0.79$) |
| 2.5.2 Longterm effect | Isabella Schwartz (2012) | -12.5 | 14.9 | 12 | -6 | 10.7 | 16 | 13.6% | -6.50 [-16.43, 3.43] |
| | S. Straudi (2013) | -5.5 | 11.9 | 8 | 0.7 | 2.3 | 8 | 15.6% | -6.20 [-14.60, 2.20] |
| | Sofia Straudi (2015) | 4.16 | 15.3 | 26 | -3.63 | 10.61 | 23 | 17.1% | 7.79 [0.48, 15.10] |
| | Subtotal (95% CI) | 46 | | | | | | 46.4% | -1.29 [-11.16, 8.57] |
| Heterogeneity: $\tau^2 = 57.04$, $Chi^2 = 8.10$, $df = 2$ ($P = 0.02$); $I^2 = 75$% |
| Test for overall effect: $Z = 0.26$ ($P = 0.80$) |

| Total (95% CI) | 92 | 94 | 100.0% | -1.07 [-6.54, 4.39] |
| Heterogeneity: $\tau^2 = 31.42$, $Chi^2 = 15.73$, $df = 5$ ($P = 0.008$); $I^2 = 68$% |
| Test for overall effect: $Z = 0.38$ ($P = 0.70$) |
| Test for subgroup differences: $Chi^2 = 0.00$, $df = 1$ ($P = 0.97$), $I^2 = 0$% |

**Figure 5** | Forest plot of comparison for the timed up and go test. Robot-assisted gait training (RAGT) versus CWT among patients with multiple sclerosis (top, post-treatment; bottom, follow-up data included).

**Figure 6** | Forest plot of comparison for stride length. Robot-assisted gait training (RAGT) versus CWT among patients with multiple sclerosis.
Only four trials have been published which evaluated balance function using the BBS in patients with MS. Our study was unable to provide any suggestions for clinical practice regarding which is the most effective treatment to improve balance function for MS patients. Based on our results, we suggest the effectiveness of RAGT on balance rehabilitation is approximately equal to CWT.

Due to the limited data, we did not detect any meaningful clinical results regarding the other parameters, such as SL and TUG. The pooled SMD calculated from each outcome did not reveal any differences between the RAGT and CWT group. The insufficient number of trials made it difficult to achieve a positive result. Moreover, the limited number of participants in each trial also made the analysis difficult. The limited number of participants is likely because the selection of patients for intervention studies is challenging, especially with the MS population, due to the variability in symptoms, the different types of MS, and the different and unpredictable course of the disease (1). Only two included clinical trials (18, 20) tested the effects of RAGT and compared it to conventional physiotherapy in patients with progressive MS and severe gait disability (EDSS 6.0–7.0). As it accounts for a large weighting (63.1%) in our analysis, we exclude these studies and make a new pooled analysis to verify whether there are still more benefits in RAGT group among patients with moderate MS (EDSS 6.0–7.0). The standard pooled MD for endurance was 0.04 (95% CI: −0.51 to 0.58, Z = 0.13, P = 0.89, F = 62%). There is no significant difference between the RAGT and CWT. Considering this limitation of our study, it takes reservations about recommending all MS patients to take RAGT as primary rehabilitation intervention. Unless patients with progressive MS can take conventional rehabilitation in early time, RAGT can be a suitable substitute.

**Study Limitations**

There are several limitations in our study. First, only one included clinical trials tested the effects of RAGT and compared it to conventional physiotherapy in patients with progressive MS and severe gait disability (EDSS 6.0–7.0), so we cannot conduct a subgroup analysis to make a more precise recommendation about the most suitable patients for RAGT. Second, the CWT group also included body-weight support gait training. With the limited data, we could not conduct a subgroup analysis to compare this training with other gait rehabilitation treatments, such as ground walking training. Third, the small number of included RCTs made the subgroup and sensitivity analysis difficult. Therefore, we did not find any clinically significant differences except for the 6MWT. Fourth, we restricted the language of the studies to English, which may have caused us to miss relevant studies published in other languages.

**CONCLUSION**

We can conclude that RAGT can bring more benefits on improving 6MWT among MS patients, but it is not enough to make a clinical significance conclusion. We take reservations about recommending all MS patients to take RAGT as primary rehabilitation intervention. With a limited amount of literature related to RAGT in people with MS, there is no significant difference in ameliorating walking speed and functional balance between RAGT and CWT. More RCTs with larger, but more homogeneous, populations are needed to conduct subgroup analysis for more precise clinical advice.

**AUTHOR CONTRIBUTIONS**

Study concepts and study design: GH and HS. Literature research and data acquisition: XX, QZ, PL, and YZ. Data analysis/interpretation and statistical analysis: HS. Manuscript preparation: XX. Manuscript editing: HS and XX. XX and HS contributed equally to this work and should be considered co-first authors.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fneur.2017.00260/full#supplementary-material.
Arch Phys Med Rehabil (2007) 88(12):1649–57. doi:10.1016/j.apmr.2007.07.032

12. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration (2011). Available from: http://handbook.cochrane.org

13. Sterne JA, Sutton AJ, Ioannidis J, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 343:d4002. doi:10.1136/bmj.d4002

14. Gandolfi M, Geroin C, Picelli A, Munari D, Waldner A, Tamburin S, et al. Robot-assisted vs. sensory integration training in treating gait and balance dysfunctions in patients with multiple sclerosis: a randomized controlled trial. Front Hum Neurosci (2014) 8:318. doi:10.3389/fnhum.2014.00318

15. Straudi S, Benedetti MG, Venturini E, Manca M, Foti C, Basaglia N. Does robot-assisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized-control trial. NeuroRehabilitation (2013) 33(4):555–63. doi:10.3233/NRE-130990

16. Vaney C, Gattlen B, Lugon-Moulin V, Meichtry A, Hausammann R, Foinant D, et al. Robotic-assisted step training (lokomat) not superior to equal intensity of over-ground rehabilitation in patients with multiple sclerosis. Neurorehabil Neural Repair (2012) 26(3):212–21. doi:10.1177/1545968311425923

17. Schwartz I, Sajin A, Moreh E, Fisher I, Neeb M, Forest A, et al. Robot-assisted gait training in multiple sclerosis patients: a randomized trial. Mult Scler J (2012) 18(6):881–90. doi:10.1177/1352458513430175

18. Beer S, Ashbacher B, Manoglu D, Gamper E, Kool J, Kesselring J. Robot-assisted gait training in multiple sclerosis: a pilot randomized trial. Mult Scler (2008) 14(2):231–6. doi:10.1177/13524585070782358

19. Lo AC, Triche EW. Improving gait in multiple sclerosis using robot-assisted, body weight supported treadmill training. Neurorehabil Neural Repair (2008) 22(6):661–71. doi:10.1177/1545968308318473

20. Straudi S, Fanciullacci C, Martinuzzi C, Pavarelli C, Rossi B, Chisari C, et al. The effects of robot-assisted gait training in progressive multiple sclerosis: a randomized controlled trial. Mult Scler (2016) 22(3):373–84. doi:10.1177/1352458515620933

21. Baert I, Freeman J, Smedal T, Dalgas U, Romberg A, Kalron A, et al. Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: a European multicenter study. Neurorehabil Neural Repair (2014) 28(7):621–31. doi:10.1177/1545968314521010

22. Gijbels D, Dalgas U, Romberg A, de Groot V, Bethoux F, Vaney C, et al. Which walking capacity tests to use in multiple sclerosis? A multicentre study providing the basis for a core set. Mult Scler (2012) 18(3):364–71. doi:10.1177/1352458511420598

23. Gijbels D, Alders G, Van Hoof E, Charlier C, Roelants M, Broekmans T, et al. Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures. Mult Scler (2010) 16(5):618–26. doi:10.1177/1352458510361357

24. Kyvelidou A, Kurz MJ, Ehlers JL, Stergiou N. Aging and partial body weight support affects gait variability. J Neuroeng Rehabil (2007) 5:22. doi:10.1186/1743-0003-5-22

25. Watt JR, Franz JR, Jackson K, Dicharry J, Riley PO, Kerrigan DC. A three-dimensional kinematic and kinetic comparison of overground and treadmill walking in healthy elderly subjects. Clin Biomech (2010) 25(5):444–9. doi:10.1016/j.clinbiomech.2009.09.002

26. Riley PO, Paolini G, Croce UD, Paylo KW, Kerrigan DC. A kinematic and kinetic comparison of overground and treadmill walking in healthy subjects. Gait Posture (2007) 26(1):17–24. doi:10.1016/j.gaitpost.2006.07.003

27. Southard V, Dave M, Davis MG, et al. The Multiple Tasks Test as a predictor of falls in older adults. Gait Posture (2005) 22(4):351–5.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Xie, Sun, Zeng, Lu, Zhao, Fan and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.